Novartis
Afinitor stops tumour growth in advanced breast cancer
July 5, 2011Manufacturing and Production, Research and Development Afinitor, Novartis, Votubia, advanced breast cancer
Novartis’ Afinitor has impressed in a late-stage trial by increasing survival in women with advanced breast cancer. The phase III …
Regulators back Novartis’ Votubia
June 28, 2011Sales and Marketing Novartis, Votubia, everolimus
Novartis’ drug Votubia has been recommended by regulators to treat a disease for which the only current option in Europe …
FDA rejects Novartis’ Ilaris for gouty arthritis
June 22, 2011Research and Development Ilaris, Novartis, gouty arthritis
An FDA advisory panel has voted against backing Novartis’ Ilaris for gouty arthritis because of safety concerns. Ilaris (canakinumab) is …
Novartis breaks ground on $500m Russian facility
June 21, 2011Manufacturing and Production Novartis, Russia, pharma manufacturing news
Novartis has started construction of its new pharmaceutical manufacturing plant in St. Petersburg, Russia.The company has broken ground on the …
Novartis eye drug wins wider European licence
June 6, 2011Sales and Marketing Lucentis, Novartis
Novartis’ Lucentis has been approved in Europe to treat people suffering from vision loss due to macular oedema secondary to …
Novartis’ Afinitor wins landmark US approval
May 6, 2011Sales and Marketing Afinitor, Novartis
Novartis’ Afinitor has been approved in the US for the treatment of progressive neuroendocrine tumours of pancreatic origin (PNET) in …
Oral MS drug Gilenya launched in the UK
April 19, 2011Sales and Marketing Novartis, gilenya, multiple sclerosis
Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …
NICE unimpressed with Novartis’ patient access scheme
April 19, 2011Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis
Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …
Novartis ends phase III trial of Tasigna
April 12, 2011GIST, Glivec, Novartis, Tasigna
Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …
Roche changes raise Novartis takeover question
March 29, 2011Sales and Marketing Novartis, Roche, mergers and acquisitions
Roche could be vulnerable to a takeover from its Swiss rival Novartis after changes in its boardroom. The Roche family …
Working Life: Novartis’ Filiberto de Cal
March 25, 2011Business Services, Sales and Marketing Novartis, Working Life, recruitment
Filiberto de Cal is director of global marketing – new products at Novartis Diagnostics. Here he outlines his route into …
FDA delays decision on Novartis’ COPD drug
March 23, 2011Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol
The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Novartis gets FDA warning letter for Puerto Rico plant
March 21, 2011Manufacturing and Production Ciba Vision, FDA manufacturing inspections, Novartis, SoftPerm contact lenses, manufacturing compliance, pharma manufacturing
A manufacturing facility operated by Novartis subsidiary Ciba Vision in Puerto Rico has been cited for manufacturing quality violations and …
Novartis plans Q2 filing for blood cancer drug
March 17, 2011Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib
Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
Novartis to close UK manufacturing site, research downsized
March 16, 2011Research and Development Horsham, Novartis, respiratory
Novartis is to close its manufacturing site in Horsham, West Sussex, but will retain its work in respiratory research at …
Latest content
FibroFind appoints Lee Borthwick as CEO
